Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineFernando P. Polack, William C. Gruber, David Cooper et al.|New England Journal of Medicine|2020Cited by 15.7k
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesUğur Şahin, Özlem Türeci, Alexander Muik et al.|Nature|2020Cited by 2.1k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsRobert W. Frenck, William C. Gruber, Nicola P. Klein et al.|New England Journal of Medicine|2021Cited by 937
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 VaccineStephen J. Thomas, Kathrin U. Jansen, Edson Duarte Moreira et al.|medRxiv|2021Cited by 144
Concurrent human antibody and T <sub>H</sub> 1 type T-cell responses elicited by a COVID-19 RNA vaccineUğur Şahin, Özlem Türeci, Alexander Muik et al.|medRxiv|2020Cited by 67